BioNTech on it's way to new highs

Positive Outlook: New ATH
Indicators: Neutral to Bullish
Trend: overall bullish
Stop-Loss: 180 EUR
Target: 220 - 240 EUR

BioNTech got the approval for it's vaccine (for the use for children at 12 or older) from the EMA end ofMay. This boosted the stock above the resistance at 169 EUR which would break the first range it's trading in. The second, much larger range, was beaten a few days after. It's defined by an inside bar on the daily view. Because of this, a fallback into that range could lead to larger consolidation. Therefore, we put our stop loss just below the last ATH. Target remains in the area between the 38,2 and 61,8 Fib (220 - 240 EUR). Next few days (1-2) will be a little bit of Mid-Consolidation before picking up again.

Let's see what happens.